share_log

Transcode Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-3i, LP(9.9%),3i Management LLC(9.9%), etc.

Transcode Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-3i, LP(9.9%),3i Management LLC(9.9%), etc.

Transcode Therapeutics | SC 13G：超過5%持股股東披露文件-3i, LP(9.9%),3i Management LLC(9.9%)等
美股SEC公告 ·  07/27 04:09
牛牛AI助理已提取核心訊息
On July 23, 2024, a Schedule 13G filing was made with the SEC by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, indicating a significant stake in TransCode Therapeutics, Inc. The filing reveals that the Reporting Persons collectively hold 1,716,600 shares of TransCode Therapeutics' common stock, representing 9.9% of the company's shares outstanding as of July 24, 2024. The shares provide shared voting and dispositive power, which are managed by 3i Management LLC, with Maier Joshua Tarlow having the authority to vote and dispose of the shares. The principal business address for all Reporting Persons is in New York, NY. The filing asserts that the acquisition of the shares is not intended to change or influence the control of the issuer, and all parties have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.
On July 23, 2024, a Schedule 13G filing was made with the SEC by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, collectively referred to as the Reporting Persons, indicating a significant stake in TransCode Therapeutics, Inc. The filing reveals that the Reporting Persons collectively hold 1,716,600 shares of TransCode Therapeutics' common stock, representing 9.9% of the company's shares outstanding as of July 24, 2024. The shares provide shared voting and dispositive power, which are managed by 3i Management LLC, with Maier Joshua Tarlow having the authority to vote and dispose of the shares. The principal business address for all Reporting Persons is in New York, NY. The filing asserts that the acquisition of the shares is not intended to change or influence the control of the issuer, and all parties have entered into a Joint Filing Agreement to file this and any subsequent amendments jointly.
2024年7月23日，由3i，LP，3i Management LLC和Maier Joshua Tarlow聯合提交的13G安排報告向美國證券交易委員會披露持有TransCode Therapeutics，Inc的重大股權。報告顯示，上述報告人共持有TransCode Therapeutics的普通股171,6600股，佔公司截至2024年7月24日已發行股份的9.9％。上述股份提供了共同投票和處分權，由3i Management LLC管理，Maier Joshua Tarlow有權投票和處置。所有報告人的主要營業地址均位於紐約。該報告稱，收購這些股份的目的不是爲了改變或影響發行人的控制，而且所有方已簽訂聯合申報協議以聯合提交此報告和任何後續修正案。
2024年7月23日，由3i，LP，3i Management LLC和Maier Joshua Tarlow聯合提交的13G安排報告向美國證券交易委員會披露持有TransCode Therapeutics，Inc的重大股權。報告顯示，上述報告人共持有TransCode Therapeutics的普通股171,6600股，佔公司截至2024年7月24日已發行股份的9.9％。上述股份提供了共同投票和處分權，由3i Management LLC管理，Maier Joshua Tarlow有權投票和處置。所有報告人的主要營業地址均位於紐約。該報告稱，收購這些股份的目的不是爲了改變或影響發行人的控制，而且所有方已簽訂聯合申報協議以聯合提交此報告和任何後續修正案。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。